From Casetext: Smarter Legal Research

Osborn v. Novartis Pharm. Corp.

United States District Court, District of New Mexico
May 4, 2023
23-cv-0212 GJF/JHR (D.N.M. May. 4, 2023)

Opinion

23-cv-0212 GJF/JHR

05-04-2023

ROBIN OSBORN, Plaintiff, v. NOVARTIS PHARMACEUTICALS CORPORATION, Defendant.


INITIAL SCHEDULING ORDER

This case is assigned to me for scheduling, case management, discovery and other non-dispositive motions. The Federal Rules of Civil Procedure, as amended, as well as the Local Rules of the Court will apply to this lawsuit.

The parties, appearing through counsel or pro se, will “meet and confer” no later than Wednesday, May 31, 2023, to formulate a provisional discovery plan. FED. R. CIV. P. 26(f). The time allowed for discovery is generally 120 to 150 days. The parties will cooperate in preparing a Joint Status Report and Provisional Discovery Plan (“JSR”) which follows the sample JSR available at the Court's web site.The blanks for suggested/proposed dates are to be filled in by the parties. Actual dates will be promulgated by order of the court shortly after entry of the JSR. Plaintiff, or Defendant in removed cases, is responsible for filing the JSR by Wednesday, June 28, 2023.

Pursuant to Administrative Order No. 06-173, the JSR replaces and supersedes the Provisional Discovery Plan and the Initial Pretrial Report, effective January 2, 2007. Please visit the Court's web site, www.nmcourt.fed.us to download the standardized Joint Status Report and Provisional Discovery Plan form.

Good cause must be shown and the Court's express and written approval obtained for any modification of the dates in the scheduling order that issue from the JSR.

Initial disclosures under FED. R. CIV. P. 26(a)(1) shall be made within fourteen (14) days of the meet-and-confer session.

A Rule 16 scheduling conference will be conducted by telephone on Friday July 14, 2023, at 9:00 a.m. Counsel shall call the following telephone number to be connected to the conference: (888) 278-0296 (access code: 9998216).

At the Rule 16 scheduling conference, counsel will be prepared to discuss discovery needs and scheduling, all claims and defenses, the use of scientific evidence and whether a Daubert hearing is needed, initial disclosures, and the time of expert disclosures and reports under FED. R. CIV. P. 26(a)(2). We will also discuss settlement prospects and alternative dispute resolution possibilities and consideration of consent pursuant to 28 U.S.C. § 636(c). Client attendance is not required. If service on all parties is not complete, plaintiff(s) appearing through counsel or pro se, is (are) responsible for notifying all parties of the content of this order.

Daubert v. Merrell Dow Pharmaceuticals, 509 U.S. 579 (1993).

Pre-trial practice in this cause shall be in accordance with the foregoing.


Summaries of

Osborn v. Novartis Pharm. Corp.

United States District Court, District of New Mexico
May 4, 2023
23-cv-0212 GJF/JHR (D.N.M. May. 4, 2023)
Case details for

Osborn v. Novartis Pharm. Corp.

Case Details

Full title:ROBIN OSBORN, Plaintiff, v. NOVARTIS PHARMACEUTICALS CORPORATION…

Court:United States District Court, District of New Mexico

Date published: May 4, 2023

Citations

23-cv-0212 GJF/JHR (D.N.M. May. 4, 2023)